Target intelligence / Profile preview

microRNA 657 (miR-657)

Target
miR-657
Molecular classification
MicroRNA, Non-coding RNA, Small regulatory RNA
01

Overview

microRNA 657 (miR-657) is a small, non-coding RNA molecule belonging to the microRNA family, typically ~22 nucleotides in length, that functions as a post-transcriptional regulator of gene expression in eukaryotic cells. Like other microRNAs, miR-657 is transcribed as a primary transcript, then processed via the Drosha/DGCR8 and Dicer pathways, finally incorporating into the RNA-induced silencing complex (RISC) to target specific mRNAs. miR-657 has been implicated in the regulation of cell proliferation and tumorigenesis, particularly in hepatocellular carcinoma, where its upregulation promotes cell proliferation and tumor development, partly by targeting transducin-like enhancer protein 1 (TLE1) and activating the NF-κB pathway. MicroRNAs such as miR-657 are also involved in broader cellular processes, including fine-tuning gene expression, buffering transcriptional programs, and contributing to disease pathogenesis when dysregulated. Therapeutic targeting of miR-657, as with other microRNAs, poses challenges related to specificity and safety.

Other names
MIR657hsa-mir-657mir-657miRNA-657MIRN657
02

Mechanism of action

Binds to 3′ untranslated regions of target mRNAs, triggering mRNA degradation or translational inhibition via the RNA-induced silencing complex (RISC)

03

Biological functions

Post-transcriptional regulation of gene expressionNegative regulation of protein synthesisRegulation of cell proliferationRegulation of tumorigenesis
04

Disease associations

Cancer (notably, hepatocellular carcinoma)Potential role in other diseases (miRNA dysregulation is widely implicated in various diseases)
05

Safety considerations

Off-target effects on gene regulation (general to miRNA therapeutics)Potential oncogenic activity if aberrantly expressed (implicated in tumorigenesis)
06

Biomarkers

Potential biomarker for hepatocellular carcinoma (based on upregulation in HCC tissues)

Beyond the preview

Go deeper on microRNA 657 (miR-657).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on microRNA 657 (miR-657).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call